PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
The conversation humorously discusses hair loss treatments, mentioning scalp massage, minoxidil, and the ineffectiveness of devices like the "Gr0wBand." It highlights the role of androgens in hair loss and suggests that increased blood flow from massage may not significantly impact hair growth.
The user is frustrated with hair loss despite using finasteride and is considering a hairpiece as a solution. Suggestions include trying a buzz cut, considering dutasteride or oral minoxidil, and addressing potential dietary issues.
Gut microbiota significantly influences androgen metabolism, impacting hair loss treatments like finasteride. Probiotics, dietary changes, and fecal microbiota transplants may help manage DHT levels and improve hair health.
The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.
People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
The conversation discusses complementary treatments for hair loss while using finasteride and minoxidil, including scalp massagers, scrubs, coconut oil, and vitamin supplements. The user seeks opinions on these additional treatments.
Using essential oil roller bottles makes applying minoxidil easier and more convenient. Oral minoxidil has potential side effects, including heart issues, while topical application is considered safer.
A 25-year-old male using 1mg Finasteride and 5% Minoxidil for hair loss experienced stabilized scalp hair but began noticing beard shedding. Users suggest that Finasteride can slow beard growth, and some recommend using Minoxidil on the beard to counteract thinning.
The post discusses the cost of oral Minoxidil and dutasteride in India. Users compare prices and share experiences with international shipping and insurance coverage for Minoxidil and finasteride.
The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.
Hair loss is influenced by genetics and sensitivity to hormones like DHT. Treatments like Minoxidil and finasteride are commonly used, and baldness persists as it doesn't affect reproductive success.
Exosomes from Musely are being discussed as a topical hair loss treatment containing ingredients like latanoprost, caffeine, cetirizine, melatonin, vitamin D3, vitamin E, and biotin. Users are curious about its effectiveness and potential side effects, noting it may take 4-6 months to see results.
The conversation discusses a hair loss flowchart for beginners, with mixed opinions on its effectiveness. Treatments mentioned include minoxidil, finasteride, dutasteride, microneedling, and vitamins.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Transitioning genders humorously suggested for hair regrowth, noting some transgender individuals experience this. Discusses treatments like minoxidil, finasteride, and hormone therapy, but advises against transitioning solely for hair regrowth.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.